The ultimate aim of all our research is to provide new knowledge and new tools that improve the lives of patients. This means translating the results of laboratory research into clinical applications in a process that makes full use of the close collaboration between our clinical and laboratory scientists. Our research projects are focused on key aspects of cell regulation most relevant to improved diagnostics and the development of novel therapies
- Non-coding RNAs / Epigenetics
- Metabolism
- Inflammation
- Niche
In addition to our work on myeloid leukemias, the appointment of Professor Uwe Platzbecker to the directorship in 2018 brings a fresh impulse with his internationally renowned expertise and achievements in the field of myelodysplasia, a condition in which the balance of white cell production is disturbed by changes in bone marrow niche.
The myelodysplasias are now recognized to involve dysregulated interaction between developing blood cells and the stromal cells that support them. Both cell types accumulate changes in a spiral of events leading ultimately to imbalanced blood cell production and an associated risk of developing leukemia. Studies of MDS therefore provide a new window onto cell interactions that are relevant to normal hematopoiesis, to MDS itself and to leukemia. We look forward to a high degree of synergy between these research areas.